జర్నల్ ఆఫ్ హైపర్‌టెన్షన్: ఓపెన్ యాక్సెస్

Doxazosin is a medication that has been used for many years in the treatment of hypertension and benign prostatic hyperplasia (BPH). BPH is a common condition in men, which causes an enlargement of the prostate gland, leading to various urinary symptoms such as difficulty urinating, weak urine flow and frequent urination. Hypertension, on the other hand, is a condition characterized by elevated blood pressure, which can lead to an increased risk of heart disease, stroke and kidney damage. Concurrent hypertension refers to the coexistence of hypertension, or high blood pressure, with one or more other medical conditions. These conditions can include diabetes, heart disease, kidney disease and sleep apnea, among others. Concurrent hypertension can be particularly concerning as it increases the risk of developing complications related to these other conditions. For example, hypertension in patients with diabetes can lead to an increased risk of cardiovascular disease, kidney damage and retinopathy.

Cardiovascular complications are a major concern in elderly patients, who are more likely to develop cardiovascular disease (CVD) due to the natural aging process and other age-related factors. These complications can have serious consequences, including heart attack, stroke and heart failure and can significantly impact a patient's quality of life. One of the most common cardiovascular complications in elderly patients is hypertension, or high blood pressure. Hypertension is a major risk factor for CVD and its prevalence increases with age. In addition, elderly patients are more likely to develop isolated systolic hypertension, a condition in which the systolic blood pressure is elevated while the diastolic pressure remains normal. Isolated systolic hypertension is particularly common in patients aged 60 years or older and has been associated with an increased risk of stroke and other cardiovascular events.

We describe a 52-year-old patient who underwent a biopsy and was found to have an inoperable right frontal-temporal-insular glioblastoma. The patient was told up front that concurrent chemo radiotherapy treatment using Temozolomide and Filicinin would be beneficial since it would provide an objective response that would allow for drastic surgery. The signal transducer and activator of transcription 3 was moderately expressed on reactive astrocytes surrounding tumour cells, according to the subsequent immunohistochemically investigations. According to our knowledge, this is the first report describing the activity of filicinin as conversion therapy in conjunction with standard treatment. It may serve as the basis for future trials that aim to validate this plan as a common neoadjuvant option for patients with unrespectable glioblastoma.